Evidence map›Paper›PMID 40338357›Full record

ArticleBiotechnology letters2025

Establishment of a high-throughput scale-down clone screening platform for intensified fed-batch culture of CHO cells.

Haiyan Luo, Shuai Wang, Collin Chong, Lile Wang, Xiaojun Sun, Qian Guo, Sam Zhang, Xiaoyue Chen, Hang Zhou, Weichang Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Haiyan LuoWuXi Biologics, Cell Line Development, Mashan, Wuxi, China.
Shuai WangWuXi Biologics, Cell Line Development, Mashan, Wuxi, China.
Collin ChongWuXi Biologics, Cell Line Development, Mashan, Wuxi, China.
Lile WangWuXi Biologics, Cell Line Development, Mashan, Wuxi, China.
Xiaojun SunWuXi Biologics, Cell Line Development, Mashan, Wuxi, China.
Qian GuoWuXi Biologics, Protein Science, Mashan, Wuxi, China.
Sam ZhangWuXi Biologics, Microbial and Viral Platforms, Economic & Technological Development Zone, Hangzhou, China.
Xiaoyue ChenWuXi Biologics, Cell Line Development, Waigaoqiao Free Trade Zone, Shanghai, China. chen_xiaoyue@wuxibiologics.com.ORCID http://orcid.org/0009-0005-8646-9786
Hang ZhouWuXi Biologics, Bioprocess Research and Development, Waigaoqiao Free Trade Zone, Shanghai, China.
Weichang ZhouWuXi Biologics, Honorary President of WuXi Biologics and Senior Advisor to CEO, Waigaoqiao Free Trade Zone, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo develop a scale-down clone screening platform for the intensified fed-batch (IFB) process to allow efficient identification of high expressing clones fitting the IFB culture strategy in bioreactor.

resultsThree monoclonal antibodies (mAbs) were used in the development and validation of the IFB specific clone screening platform for CHO cells. The IFB platform significantly improved titer levels, achieving an average titer of 8 g/L and the highest titer of 9.6 g/L. With similar cell viability, lactate profile and titer levels, both the spin tube model and the AMBR250

conclusionThis IFB-process specific clone screening serves as an alternative platform for industry application that can increase the effectiveness and efficiency of screening high-expressing CHO cell lines for IFB production.

Indexed as

Antibodies, MonoclonalBatch Cell Culture TechniquesHigh-Throughput Screening AssaysAnimalsBioreactorsCell SurvivalCHO CellsCricetulusAntibodies, MonoclonalCHO cell cultureClone screeningIntensified fed-batchMammalian cell line development

Identifiers

PMID40338357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.